Literature DB >> 24170413

Unbalanced estrogen metabolism in ovarian cancer.

Muhammad Zahid1, Cheryl L Beseler, James B Hall, Tricia LeVan, Ercole L Cavalieri, Eleanor G Rogan.   

Abstract

Greater exposure to estrogens is a risk factor for ovarian cancer. To investigate the role of estrogens in ovarian cancer, a spot urine sample and a saliva sample were obtained from 33 women with ovarian cancer and 34 age-matched controls. Thirty-eight estrogen metabolites, conjugates and DNA adducts were analyzed in the urine samples using ultraperformance liquid chromatography/tandem mass spectrometry, and the ratio of adducts to metabolites and conjugates was calculated for each sample. The ratio of depurinating estrogen-DNA adducts to estrogen metabolites and conjugates was significantly higher in cases compared to controls (p < 0.0001), demonstrating high specificity and sensitivity. DNA was purified from the saliva samples and analyzed for genetic polymorphisms in the genes for two estrogen-metabolizing enzymes. Women with two low-activity alleles of catechol-O-methyltransferase plus one or two high-activity alleles of cytochrome P450 1B1 had higher levels of estrogen-DNA adducts and were more likely to have ovarian cancer. These findings indicate that estrogen metabolism is unbalanced in ovarian cancer and suggest that formation of estrogen-DNA adducts plays a critical role in the initiation of ovarian cancer.
© 2013 UICC.

Entities:  

Keywords:  CYP1B1; SNPs; catechol-O-methyltransferase; ovarian cancer, estrogen-DNA adducts, unbalanced estrogen metabolism

Mesh:

Substances:

Year:  2014        PMID: 24170413      PMCID: PMC3949171          DOI: 10.1002/ijc.28565

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  36 in total

1.  Estrogen bioactivation, genetic polymorphisms, and ovarian cancer.

Authors:  Thomas A Sellers; Joellen M Schildkraut; V Shane Pankratz; Robert A Vierkant; Zachary S Fredericksen; Janet E Olson; Julie Cunningham; William Taylor; Mark Liebow; Carol McPherson; Lynn C Hartmann; Tuya Pal; Araba A Adjei
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-11       Impact factor: 4.254

2.  The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity.

Authors:  Muhammad Zahid; Ekta Kohli; Muhammad Saeed; Eleanor Rogan; Ercole Cavalieri
Journal:  Chem Res Toxicol       Date:  2006-01       Impact factor: 3.739

3.  A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio.

Authors:  Valentina Paracchini; Paola Pedotti; Sara Raimondi; Seymour Garte; H Leon Bradlow; Daniel W Sepkovic; Emanuela Taioli
Journal:  Clin Chem Lab Med       Date:  2005       Impact factor: 3.694

4.  Potential biomarker for early risk assessment of prostate cancer.

Authors:  Y Markushin; N Gaikwad; H Zhang; P Kapke; E G Rogan; E L Cavalieri; B J Trock; C Pavlovich; R Jankowiak
Journal:  Prostate       Date:  2006-10-01       Impact factor: 4.104

5.  Evaluation of serum estrogen-DNA adducts as potential biomarkers for breast cancer risk.

Authors:  Sandhya Pruthi; Li Yang; Nicole P Sandhu; James N Ingle; Cheryl L Beseler; Vera J Suman; Ercole L Cavalieri; Eleanor G Rogan
Journal:  J Steroid Biochem Mol Biol       Date:  2012-02-24       Impact factor: 4.292

6.  Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms.

Authors:  S Dawling; N Roodi; R L Mernaugh; X Wang; F F Parl
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

7.  Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens.

Authors:  R R Newbold; J G Liehr
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

8.  Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity.

Authors:  I H Hanna; S Dawling; N Roodi; F P Guengerich; F F Parl
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

9.  Synthesis and structure elucidation of estrogen quinones conjugated with cysteine, N-acetylcysteine, and glutathione.

Authors:  K Cao; D E Stack; R Ramanathan; M L Gross; E G Rogan; E L Cavalieri
Journal:  Chem Res Toxicol       Date:  1998-08       Impact factor: 3.739

10.  Urine biomarkers of risk in the molecular etiology of breast cancer.

Authors:  Nilesh W Gaikwad; Li Yang; Sandhya Pruthi; James N Ingle; Nicole Sandhu; Eleanor G Rogan; Ercole L Cavalieri
Journal:  Breast Cancer (Auckl)       Date:  2009-01-06
View more
  14 in total

1.  Human Biomonitoring of DNA Adducts by Ion Trap Multistage Mass Spectrometry.

Authors:  Jingshu Guo; Robert J Turesky
Journal:  Curr Protoc Nucleic Acid Chem       Date:  2016-09-01

2.  Loss of NQO1 generates genotoxic estrogen-DNA adducts in Fuchs Endothelial Corneal Dystrophy.

Authors:  Taiga Miyajima; Geetha Melangath; Shan Zhu; Neha Deshpande; Shivakumar Vasanth; Bodhisattwa Mondal; Varun Kumar; Yuming Chen; Marianne O Price; Francis W Price; Eleanor G Rogan; Muhammad Zahid; Ula V Jurkunas
Journal:  Free Radic Biol Med       Date:  2019-12-17       Impact factor: 7.376

3.  Ultraviolet A light induces DNA damage and estrogen-DNA adducts in Fuchs endothelial corneal dystrophy causing females to be more affected.

Authors:  Cailing Liu; Taiga Miyajima; Geetha Melangath; Takashi Miyai; Shivakumar Vasanth; Neha Deshpande; Varun Kumar; Stephan Ong Tone; Reena Gupta; Shan Zhu; Dijana Vojnovic; Yuming Chen; Eleanor G Rogan; Bodhiswatta Mondal; Muhammad Zahid; Ula V Jurkunas
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-18       Impact factor: 11.205

4.  Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.

Authors:  Sateesh Reddy Nallapalle; Sarika Daripally; V T S Vidudala Prasad
Journal:  Tumour Biol       Date:  2014-12-04

5.  The ovarian carcinoma risk with the polymorphisms of CYP1B1 come from the positive selection.

Authors:  Liying Zhang; Liyuan Feng; Meng Lou; Xihan Deng; Chuanzhong Liu; Li Li
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

6.  Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the B ∼ FIT Cohort.

Authors:  Cher M Dallal; James V Lacey; Ruth M Pfeiffer; Douglas C Bauer; Roni T Falk; Diana S M Buist; Jane A Cauley; Trisha F Hue; Andrea Z LaCroix; Jeffrey A Tice; Timothy D Veenstra; Xia Xu; Louise A Brinton
Journal:  Horm Cancer       Date:  2016-01-04       Impact factor: 3.869

7.  CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.

Authors:  Zhuangyan Zhu; Yaqin Mu; Caixia Qi; Jian Wang; Guoping Xi; Juncheng Guo; Ruoran Mi; Fuxi Zhao
Journal:  Int J Mol Med       Date:  2014-12-16       Impact factor: 4.101

Review 8.  Dietary fat intake and ovarian cancer risk: a meta-analysis of epidemiological studies.

Authors:  Wenlong Qiu; Heng Lu; Yana Qi; Xiuwen Wang
Journal:  Oncotarget       Date:  2016-06-14

9.  Etiology and prevention of prevalent types of cancer.

Authors:  Ercole L Cavalieri; Eleanor G Rogan
Journal:  J Rare Dis Res Treat       Date:  2017-05-02

Review 10.  Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention.

Authors:  Ercole L Cavalieri; Eleanor G Rogan
Journal:  Clin Transl Med       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.